

Information for Vermont Prescribers of Prescription Drugs (Long Form)

Oxbryta® (voxelotor) Tablets

Oxbryta® (voxelotor) Tablets for Oral Suspension

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

Product Name	Manufacturer	NDC or UPC	Pkg Size	AWP Per Pkg	AWP Per Pill
Marketed Product					
Oxbryta 300 mg Tablets for Oral Suspension	Global Blood Therapeutics, Inc.	72786-111-02	60 EA	\$12,500.40	\$208.34
Oxbryta 300 mg Tablets for Oral Suspension	Global Blood Therapeutics, Inc.	72786-111-03	90 EA	\$12,500.40	\$138.89
Oxbryta 500 mg Tablet	Global Blood Therapeutics, Inc.	72786-101-01	90 EA	\$12,500.40	\$138.89
Other Products					
crizanlizumab-tmca 100 mg/10 mL (10 mg/mL) IV solution	Novartis Pharmaceuticals Corporation	0078-0883-61	Non-Pill Product		

IBM Micromedex® RED BOOK® is the source of this data. Reprinted with permission by IBM Micromedex® RED BOOK®.
Data as of January 7, 2022

Oxbryta is a registered trademark of Global Blood Therapeutics, Inc.